Prior large series show that IGH translocations occur in a small minority of CLL cases and encompass biologically heterogeneous partners: patients with IGH::BCL2 often display trisomy 12 and atypical morphologic or immunophenotypic features and may have outcomes comparable to low-risk FISH subsets, whereas IGH::BCL3 rearrangements are more consistently linked to higher risk scores and earlier need for therapy [28,29]. Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.